Natco Pharma Ltd Share Price – NSE  / BSE

Pharmaceuticals, Small Cap

The approved product is bioequivalent to Halaven Injection, the reference-listed drug (RLD) marketed by Eisai Inc.

Eribulin Mesylate Injection is indicated for the treatment of adults with metastatic breast cancer who have previously undergone at least two chemotherapy regimens for metastatic disease. It is also used for the treatment of patients with unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen.

According to IQVIA MAT data for April 2026, the reference drug Halaven recorded estimated annual sales of approximately $43.7 million in the United States.

NATCO Pharma, headquartered in Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The company reported a 34.11% year-on-year decline in consolidated net profit to Rs 267.9 crore in Q4 FY26, compared with Rs 406.6 crore posted in the corresponding quarter last year. Revenue from operations fell 39.46% YoY to Rs 739.1 crore in the quarter ended 31 March 2026. The counter slipped 2.48% to Rs 915.80 on the BSE.

Lupin is a global pharmaceutical company focused on branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapeutic segments. The company?s consolidated profit after tax stood at Rs 1,468.70 crore in Q4 FY26, up 87.72% from Rs 782.40 crore in Q4 FY25 and higher by 24.42% from Rs 1,180.50 crore in Q3 FY26. Net sales rose 32.9% to Rs 7391.91 crore in Q4 FY26 from Rs 5562.2 crore in Q4 FY25. It increased 4.1% sequentially from Rs 7100.5 crore in Q3 FY26. The counter shed 0.20% to Rs 2,245.10 on the BSE.

Powered by Capital Market - Live News

Revenue from operations fell 39.46% YoY to Rs 739.1 crore in the quarter ended 31 March 2026.

Profit before tax (PBT) declined sharply by 71.51% to Rs 144.1 crore in Q4 FY26 from Rs 505.9 crore recorded in Q4 FY25.

On the segmental front, revenue from the pharmaceuticals business stood at Rs 716.5 crore, down 40.58% year-on-year. Meanwhile, revenue from the agro chemicals segment increased 50.66% YoY to Rs 716.5 crore in Q4 FY26.

For the full financial year FY26, Natco Pharma reported a 24.76% decline in consolidated net profit to Rs 1,418.5 crore. Revenue from operations decreased 7.92% year-on-year to Rs 4,078.3 crore in FY26.

NATCO Pharma, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products.

Powered by Capital Market - Live News

Delta Corp Ltd, ISGEC Heavy Engineering Ltd, Jyoti CNC Automation Ltd and Bharat Dynamics Ltd are among the other losers in the BSE's 'A' group today, 29 May 2026.

Natco Pharma Ltd tumbled 10.70% to Rs 1049.8 at 14:46 IST.The stock was the biggest loser in the BSE's 'A' group.On the BSE, 1.18 lakh shares were traded on the counter so far as against the average daily volumes of 53556 shares in the past one month.

Delta Corp Ltd lost 8.62% to Rs 74.01. The stock was the second biggest loser in 'A' group.On the BSE, 26.91 lakh shares were traded on the counter so far as against the average daily volumes of 2.64 lakh shares in the past one month.

ISGEC Heavy Engineering Ltd crashed 8.55% to Rs 944.4. The stock was the third biggest loser in 'A' group.On the BSE, 10635 shares were traded on the counter so far as against the average daily volumes of 3711 shares in the past one month.

Jyoti CNC Automation Ltd dropped 8.06% to Rs 604. The stock was the fourth biggest loser in 'A' group.On the BSE, 5.14 lakh shares were traded on the counter so far as against the average daily volumes of 70030 shares in the past one month.

Bharat Dynamics Ltd fell 7.90% to Rs 1182. The stock was the fifth biggest loser in 'A' group.On the BSE, 5.14 lakh shares were traded on the counter so far as against the average daily volumes of 89799 shares in the past one month.

Powered by Capital Market - Live News

Natco Pharma will hold a meeting of the Board of Directors of the Company on 29 May 2026.